Perfil da empresa · Healthcare

Merck KGaA

MRK · XETRA
Bolsa
XETRA
País / Região
Germany
Funcionários
59.077
Preço atual
136.45
Ao vivo · 11 de junho de 2026
Compra justa
≤ €95
Entrada com margem de segurança
Pontuação de Crescimento Baillie
49/100
Fraco
Valor intrínseco · Faixa em três níveis Preço atual €136.45 Ao vivo · Dentro da faixa de valor intrínseco justo

Faixa de valuation composta · conservador €90–€95 / justo €119–€161 / otimista €180–€195. A €136.45, Dentro da faixa de valor intrínseco justo.

Na publicação €133.05 (19 de junho de 2026)

Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA is a subsidiary of E. Merck KG.

Valor de mercado€ 57,41 bi
Receita (TTM)€ 20,96 bi
EBITDA€ 5,67 bi
Margem líquida12,08%
ROE8,53%
P/L (TTM)22,65
P/L projetado19,34
PEG2,61
LPA€ 5,83
Dividend yield1,66%
Faixa de 52 semanas€ 98,72 – € 140,25

Dados da EODHD, apresentados na moeda de reporte; apenas para referência, não constitui recomendação de investimento.

História

Em breveEsta seção está sendo preenchida — volte em breve.

Posição no setor

Em breveEsta seção está sendo preenchida — volte em breve.